These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19497744)
21. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors. Zhu Y; Ding X; Yu D; Chong H; He Y J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552 [TBL] [Abstract][Full Text] [Related]
22. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047 [TBL] [Abstract][Full Text] [Related]
23. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527 [TBL] [Abstract][Full Text] [Related]
24. Design and Biological Evaluation of Meng G; Pu J; Li Y; Han A; Tian Y; Xu W; Zhang T; Li X; Lu L; Wang C; Jiang S; Liu K J Med Chem; 2019 Oct; 62(19):8773-8783. PubMed ID: 31513410 [TBL] [Abstract][Full Text] [Related]
25. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor. Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981 [TBL] [Abstract][Full Text] [Related]
26. Peptide and non-peptide HIV fusion inhibitors. Jiang S; Zhao Q; Debnath AK Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159 [TBL] [Abstract][Full Text] [Related]
27. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. Su S; Ma Z; Hua C; Li W; Lu L; Jiang S Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603 [TBL] [Abstract][Full Text] [Related]
28. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. He Y Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277 [TBL] [Abstract][Full Text] [Related]
29. Bivalent HIV-1 fusion inhibitors based on peptidomimetics. Kobayakawa T; Ebihara K; Tsuji K; Kawada T; Fujino M; Honda Y; Ohashi N; Murakami T; Tamamura H Bioorg Med Chem; 2020 Dec; 28(24):115812. PubMed ID: 33157478 [TBL] [Abstract][Full Text] [Related]
30. A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Su S; Rasquinha G; Du L; Wang Q; Xu W; Li W; Lu L; Jiang S Molecules; 2019 Mar; 24(6):. PubMed ID: 30901967 [TBL] [Abstract][Full Text] [Related]
31. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053 [TBL] [Abstract][Full Text] [Related]
32. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor. Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334 [TBL] [Abstract][Full Text] [Related]
34. Lipophilic and amphiphilic interactions in glycoprotein 41: targets for therapy. Gochin M Curr Top Med Chem; 2011 Dec; 11(24):2945-6. PubMed ID: 22044224 [No Abstract] [Full Text] [Related]
35. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. Pan C; Cai L; Lu H; Lu L; Jiang S J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094 [TBL] [Abstract][Full Text] [Related]
36. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219 [TBL] [Abstract][Full Text] [Related]
37. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. Pan C; Liu S; Jiang S J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833 [TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. Gustchina E; Louis JM; Bewley CA; Clore GM J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381 [TBL] [Abstract][Full Text] [Related]
39. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576 [TBL] [Abstract][Full Text] [Related]
40. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation. Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]